Breast Cancer Clinical Trials in Pennsylvania

Showing 161-180 of 602 trials

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with breast cancer treated with chemotherapy.

Breast Carcinoma

University of Rochester NCORP Research Base1,363 participantsStarted Apr 2018

Honolulu, Hawaii, United States • Decatur, Illinois, United States • New Orleans, Louisiana, United States +15 more locations

Active Not RecruitingPhase 350 miles

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).

Triple Negative Breast CancerPD-L1 Positive

Gilead Sciences443 participantsStarted Jul 2022

Anchorage, Alaska, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +501 more locations

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Breast Cancer Trials in Other Cities

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Proton Radiation for Stage II/III Breast Cancer

MarginProbe 2.0 Data Collection Protocol

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Other Conditions in Pennsylvania